FATE – Fate Therapeutics, Inc.
Float Short %
10.45
Margin Of Safety %
Put/Call OI Ratio
0.12
EPS Next Q Diff
-0.01
EPS Last/This Y
0.49
EPS This/Next Y
0.02
Price
1.45
Target Price
4.94
Analyst Recom
2.09
Performance Q
43.14
Upside
-1,275.3%
Beta
2.2
Ticker: FATE
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-23 | FATE | 1.21 | 0.16 | 0.03 | 7083 |
| 2026-01-26 | FATE | 1.235 | 0.16 | 0.02 | 7342 |
| 2026-01-27 | FATE | 1.305 | 0.14 | 0.00 | 8040 |
| 2026-01-28 | FATE | 1.22 | 0.14 | 0.36 | 8275 |
| 2026-01-29 | FATE | 1.19 | 0.14 | 0.05 | 8343 |
| 2026-01-30 | FATE | 1.19 | 0.13 | 0.04 | 8454 |
| 2026-02-02 | FATE | 1.225 | 0.13 | 0.27 | 8661 |
| 2026-02-03 | FATE | 1.155 | 0.13 | 0.42 | 8723 |
| 2026-02-05 | FATE | 1.055 | 0.13 | 0.23 | 9031 |
| 2026-02-09 | FATE | 1.125 | 0.12 | 0.38 | 9229 |
| 2026-02-10 | FATE | 1.09 | 0.12 | 1.00 | 9237 |
| 2026-02-11 | FATE | 1.175 | 0.12 | 999.99 | 9238 |
| 2026-02-12 | FATE | 1.2 | 0.12 | 0.01 | 9291 |
| 2026-02-13 | FATE | 1.255 | 0.12 | 0.10 | 9492 |
| 2026-02-17 | FATE | 1.34 | 0.12 | 0.01 | 9484 |
| 2026-02-18 | FATE | 1.365 | 0.12 | 0.01 | 9252 |
| 2026-02-19 | FATE | 1.39 | 0.13 | 0.00 | 9155 |
| 2026-02-20 | FATE | 1.455 | 0.12 | 0.31 | 9742 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-23 | FATE | 1.21 | 37.6 | - | -1.15 |
| 2026-01-26 | FATE | 1.24 | 37.6 | - | -1.15 |
| 2026-01-27 | FATE | 1.31 | 37.6 | - | -1.15 |
| 2026-01-28 | FATE | 1.22 | 37.6 | - | -1.15 |
| 2026-01-29 | FATE | 1.20 | 37.6 | - | -1.15 |
| 2026-01-30 | FATE | 1.19 | 37.6 | - | -1.15 |
| 2026-02-02 | FATE | 1.23 | 37.6 | - | -1.15 |
| 2026-02-03 | FATE | 1.16 | 37.6 | - | -1.15 |
| 2026-02-04 | FATE | 1.14 | 37.6 | - | -1.15 |
| 2026-02-05 | FATE | 1.05 | 37.6 | - | -1.15 |
| 2026-02-06 | FATE | 1.13 | 37.6 | - | -1.15 |
| 2026-02-09 | FATE | 1.13 | 37.6 | - | -1.15 |
| 2026-02-10 | FATE | 1.10 | 37.6 | - | -1.15 |
| 2026-02-11 | FATE | 1.18 | 37.6 | - | -1.15 |
| 2026-02-12 | FATE | 1.20 | 37.6 | - | -1.15 |
| 2026-02-13 | FATE | 1.25 | 37.6 | - | -1.15 |
| 2026-02-17 | FATE | 1.34 | 37.6 | - | -1.15 |
| 2026-02-18 | FATE | 1.37 | 37.6 | - | -1.15 |
| 2026-02-19 | FATE | 1.39 | 37.6 | - | -1.15 |
| 2026-02-20 | FATE | 1.45 | 38.4 | - | -1.15 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-01-23 | FATE | -0.64 | 1.72 | 9.21 |
| 2026-01-26 | FATE | -0.64 | 1.72 | 9.21 |
| 2026-01-27 | FATE | -0.64 | 1.72 | 9.21 |
| 2026-01-28 | FATE | -0.64 | 1.72 | 10.47 |
| 2026-01-29 | FATE | -0.64 | 1.72 | 10.47 |
| 2026-01-30 | FATE | -0.64 | 1.72 | 10.47 |
| 2026-02-02 | FATE | -0.64 | 1.69 | 10.47 |
| 2026-02-03 | FATE | -0.64 | 1.69 | 10.47 |
| 2026-02-04 | FATE | -0.64 | 1.69 | 10.47 |
| 2026-02-05 | FATE | -0.64 | 1.69 | 10.47 |
| 2026-02-06 | FATE | -0.26 | 1.69 | 10.47 |
| 2026-02-09 | FATE | -0.26 | 2.31 | 10.47 |
| 2026-02-10 | FATE | -0.26 | 2.31 | 10.47 |
| 2026-02-11 | FATE | -0.26 | 2.31 | 10.44 |
| 2026-02-12 | FATE | -0.26 | 2.31 | 10.44 |
| 2026-02-13 | FATE | -0.26 | 2.31 | 10.44 |
| 2026-02-17 | FATE | -0.26 | 4.19 | 10.44 |
| 2026-02-18 | FATE | -0.26 | 4.19 | 10.44 |
| 2026-02-19 | FATE | -0.26 | 4.19 | 10.44 |
| 2026-02-20 | FATE | -0.26 | 4.19 | 10.45 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.27
Avg. EPS Est. Current Quarter
-0.27
Avg. EPS Est. Next Quarter
-0.28
Insider Transactions
-0.26
Institutional Transactions
4.19
Beta
2.2
Average Sales Estimate Current Quarter
1
Average Sales Estimate Next Quarter
Fair Value
Quality Score
13
Growth Score
23
Sentiment Score
96
Actual DrawDown %
98.7
Max Drawdown 5-Year %
-99.4
Target Price
4.94
P/E
Forward P/E
PEG
P/S
23.59
P/B
0.72
P/Free Cash Flow
EPS
-1.32
Average EPS Est. Cur. Y
-1.15
EPS Next Y. (Est.)
-1.13
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-2187.11
Relative Volume
1.31
Return on Equity vs Sector %
-95.7
Return on Equity vs Industry %
-78.2
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.05
EBIT Estimation
Fate Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 181
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
stock quote shares FATE – Fate Therapeutics, Inc. Stock Price stock today
news today FATE – Fate Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch FATE – Fate Therapeutics, Inc. yahoo finance google finance
stock history FATE – Fate Therapeutics, Inc. invest stock market
stock prices FATE premarket after hours
ticker FATE fair value insiders trading